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Background: Pharmacotherapy in the older adult is a complex field involving several different medical
professionals. The evidence base for pharmacotherapy in elderly patients in primary care relies on only a few
clinical trials, thus documentation must be improved, particularly in the field of complementary and alternative
medicine (CAM) like phytotherapy, homoeopathy, and anthroposophic medicine. This study describes diagnoses
and therapies observed in elderly patients treated with anthroposophic medicine in usual care.
Methods: Twenty-nine primary care physicians in Germany participated in this prospective, multicenter
observational study on prescribing patterns. Prescriptions and diagnoses were reported for each consecutive
patient. Data were included if patients were at least 60 years of age. Multiple logistic regression analysis was used
to determine factors associated with anthroposophic prescriptions.
Results: In 2005, a total of 12 314 prescriptions for 3076 patients (68.1% female) were included. The most frequent
diagnoses were hypertension (11.1%), breast cancer (3.5%), and heart failure (3.0%). In total, 30.5% of the prescriptions
were classified as CAM remedies alone, 54.4% as conventional pharmaceuticals alone, and 15.1% as a combination of
both. CAM remedies accounted for 41.7% of all medications prescribed (35.5% anthroposophic). The adjusted odds ratio
(AOR) for receiving an anthroposophic remedy was significantly higher for the first consultation (AOR = 1.65; CI: 1.52-
1.79), treatment by an internist (AOR = 1.49; CI: 1.40-1.58), female patients (AOR = 1.35; CI: 1.27-1.43), cancer (AOR = 4.54;
CI: 4.12-4.99), arthropathies (AOR = 1.36; CI: 1.19-1.55), or dorsopathies (AOR = 1.34; CI: 1.16-1.55) and it decreased with
patient age (AOR = 0.97; CI: 0.97-0.98). The likelihood of being prescribed an anthroposophic remedy was especially low
for patients with hypertensive diseases (AOR = 0.36; CI: 0.32-0.39), diabetes mellitus (AOR = 0.17; CI: 0.14-0.22), or
metabolic disorders (AOR = 0.17; CI: 0.13-0.22).
Conclusion: The present study is the first to provide a systematic overview of everyday anthroposophic medical
practice in primary care for elderly patients. Practitioners of anthroposophic medicine prescribe both conventional
and complementary treatments. Our study may facilitate further CAM-research on indications of, for example,
dementia or adverse drug reactions in the elderly.
Background
With average life expectancy increasing and birth rates
declining, the proportion of elderly people expands in
almost every developed country. Due to this demographic
shift, in Germany the proportion of elderly people is
expected to rise from 20 to 34% within the next decades.
Particularly, the proportion of people aged 80 years or
older will rise from 5% today to 14% in 2060 [1].
Bearing this development in mind, pharmacotherapy
in an aging society is a challenge that will be faced in
upcoming years. Increasing age will go hand-in-hand
with the prevalence of many diseases and this will,
therefore, lead to higher prescription drug consumption.
According to data from German health insurance com-
panies, in 2005 the proportion of drug users among the * Correspondence: ejeschke@havelhoehe.de
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75 produced 90% of drug-related costs [2].
While there is a broad field of research that analyzes
pharmacological treatments in the middle aged popula-
tion, there is a substantial knowledge gap in the study of
pharmacotherapy in elderly patients [3]. This is mainly
due to the fact that available data on pharmacotherapy
in the elderly is widespread and older people are often
excluded from trials. Even in cases where there is clini-
cal data on the effects of pharmacology in elderly
patients, prescribing patterns in primary care are often
unknown, which is peculiar considering the elderly are
the main users of pharmacotherapy.
O n ea s p e c tt h a th a sm o r eo rl e s sb e e nn e g l e c t e di n
health services research is the prescription of comple-
mentary drugs to elderly patients in primary care. The
use of complementary and alternative medicine (CAM)
among elderly persons is of worldwide significance and
of increasing interest [4-7]. Some evidence has also
shown that CAM is used for elderly patients with special
conditions, like cancer [8,9], hypertension [10], or men-
tal disorders [11]. This is often the result of self-medica-
tion but it is also prescribed by physicians. For instance,
14.5% of women with cancer consulted an alternative
practitioner in Australia within a span of 12 months [9].
In the elderly, concurrent use of CAM products and
conventional medicines was found to be common [12].
T h e r ea r eo n l yaf e wh i n t sa st ow h e n ,h o w ,a n di n
what amount physicians, particularly those related to
CAM, prescribe complementary medicine drugs to
elderly patients. To fill this knowledge gap, the EvaMed
project was launched by physicians specializing in
anthroposophic medicine (AM) [13]. AM is a medical
system that was founded in the 1920s by Rudolf Steiner
and Ita Wegman [14]. Apart from physical therapies like
rhythmical embrocations [15], therapeutic eurythmy
[16], or creative art therapies [17], AM offers a broad
variety of pharmacological therapies. AM, however, is
not an isolated system; it regards itself as an extension
of conventional treatment, requiring the physician to
combine both conventional and anthroposophic treat-
ments to an individualized and personalized treatment
regimen to stimulate the capacity of the patient for self-
healing.
Anthroposophic remedies are based on preparations of
mineral, botanical, or zoological origins as well as che-
mically defined substances that are either undiluted or
based on the homoeopathic principle of high dilution.
In the field of oncology, for example, anthroposophic
remedies based on mistletoe extracts are the most
important drugs in Germany. According to a survey by
Münstedt et al., every third GP (35%) prefers mistletoe
extracts for the treatment of cancer patients [18].
Anthroposophical pharmacotherapy also provides
combined preparations. Cardiodoron®, for example, a
composition of extracts from Primula officinalis and
Onopordon acanthium blossoms combined with extracts
from the herb Hyoscyamus niger, is frequently pre-
scribed for cardio-respiratory coordination, such as for
patients with orthostatic symptoms [19].
Implemented in the German Drug Law, AM together
with homeopathy and phytotherapy are summarized as
“special therapeutic directions”. Note that pharmaceuti-
cal ingredients like Hypericum perforatum (St. John’s
wort) by means of their manufacturing may occur in all
three special therapeutic directions. On the drug level,
however, the classification is distinct; every CAM-related
drug therapy according to the pharmaceutical prepara-
tion is assigned only to one of these directions.
To offer insight into the field of CAM-related pharma-
cotherapy in elderly patients, this analysis aims to inves-
tigate the prescribing patterns for this group of patients.
Methods
In total, 29 primary care physicians in Germany partici-
pated in this prospective, multicenter observational
study. All were members of the EvaMed Pharmacovigi-
lance Network, which since 2004 has aimed to evaluate
complementary remedies in usual care with regard to
prescribing patterns, efficacy, and safety [13,20]. Physi-
cians were recruited through the German National
Association of Anthroposophic Physicians (Gesellschaft
Antroposophischer Ärzte in Deutschland;G A Ä D ) .A
total of 362 physicians were contacted and informed
about the EvaMed Network by standard mail and, in the
event of no response, four weeks later by telephone. For
a physician to be eligible to participate in the study, his
or her medical practice had to meet a number of techni-
cal requirements, including the presence of a special
computerized patient documentation system (DocEx-
pert, DocConcept, TurboMed, Duria, AdamedPlus,
Medistar), a local area network (LAN) connection, and
Microsoft Windows and Internet Explorer (i.e. as client
software). A total of 38 physicians (10.5%) fulfilled the
technical requirements, gave informed consent, and
agreed to participate in the EvaMed Network. Of these
physicians, the 9 who specialized in paediatrics were
excluded from the study. Each of the remaining 29 phy-
sicians had practised for at least five years in primary
care in addition to completing training in anthropo-
sophic medicine.
The study period lasted from January through Decem-
ber 2005. Data were included in the analysis if patients
were at least 60 years old and had received drug treat-
ment at least once during the study period.
During the study, participating physicians continued
to follow their routine documentation procedures,
recording all treatment relevant diagnoses and all
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existing computerized patient documentation system.
These data were exported to the QuaDoSta postgreSQL-
database system hosted in each practice [21]. After com-
pleting each export, participating physicians used a
browser-based interface to match individual diagnoses
with the corresponding drugs or remedies that had been
prescribed. After receiving the data sets, study investiga-
tors checked the data for completeness (e.g. matching
diagnoses with remedies). If necessary, the study center
phoned the physicians and asked them to supply any
missing data.
Diagnoses were coded according to the 10th revision of
the International Classification of Diseases (ICD-10). Pre-
scribed drugs were documented using the German
National Drug Code (German: Pharmazentralnummer;
PZN). Medications were classified as anthroposophic,
homoeopathic, phytotherapeutic, or conventional accord-
ing to the German ABDA database (ABDA = German
acronym for the Federal Confederation of German Phar-
macist Associations), which contains a broad range of
data on all currently available medicinal drugs and sub-
stances. ‘Anthroposophic’, ‘homoeopathic’,a n d‘phy-
totherapeutic’ were defined according to the regulations
of the German Drug Law and are referred to below as
‘CAM remedies’. Overall medication regimens were clas-
sified as consisting of CAM remedies alone, conventional
pharmaceuticals alone, or a combination of both.
The present study is based on secondary data provided
by physicians. As such, the recommendations for good
practice in secondary data analysis (e.g. anonymization of
data on prescriptions and diagnoses) developed by the
German Working Group on the Collection and Use of Sec-
ondary Data [22] were applied in full. In addition, the study
was approved by the responsible data security official.
Statistical analysis was performed with SPSS 16.0 for
Windows. Descriptive analysis was used to determine
prescription rates. Means and standard deviations (SD)
were calculated for continuous data. In cases where data
were not normally distributed, medians and interquartile
ranges (IQR) were reported. The two-tailed chi-square
test was used to analyze differences in prescription rates
and the Cochran-Armitage test was used as a measure
of age-related trends in prescription rates. The Kruskal-
Wallis test was used to analyze differences in medians
of prescriptions and prescribed medications among
groups. The significance level was set at a = 0.05. Sub-
group analyses were performed for patient gender, age
(60-74 years; 75-79 years, 80 years or older), and diag-
nosis (ICD-10 chapters), as well as for drug type, medi-
cation regimen, physician specialization, and
consultation type (first vs. follow up).
As a precursor to multivariate analysis, univariate ana-
lysis with bonferroni correction was carried out to
determine factors associated with the prescription of
anthroposophic remedies. We included consultation
type (first vs. follow up), physician specialization, patient
age and sex, ICD10-diagnoses groups, number of diag-
noses, and number of prescribed remedies at admission
as relevant variables in our analysis. Associations were
analysed in the complete study population and across
age strata.
A multiple logistic regression model was then con-
ducted using a stepwise backward selection based on
the likelihood ratio statistics. Adjusted odds ratios
(AOR) and 95% confidence intervals (CI) were calcu-
lated. The dependent variable was the prescribing of any
anthroposophic remedy. Significant results of univariate
analysis that were independly associated with prescribing
anthroposophic remedies were included as independent
variables in the logistic regression model. Patient age
was introduced in the model as a continuous, centered
variable. Multicollinearity and interactions between
independent predictors were investigated. The Hosmer-
Lemeshow goodness-of-fit test was used to assess how
well the chosen model fits the data (c




Of the 29 participating physicians, 21 (72%) were GPs and
8 (28%) were specialists (including 4 (14%) internists). The
participating physicians did not differ significantly from
the overall population of physicians certified in anthropo-
sophic treatment in Germany in 2005 (n = 362) in terms
of mean age (49.1 ± 6.1 years vs. 47.5 ± 6.1 years;
P = 0.175) or gender (58.1% vs. 62.2% males; P = 0.662)
and they were only slightly younger and consisted of a
similar percentage of women compared to all office-based
physicians in Germany (mean 52.0 years; 61.2% men) [23].
Patients and prescriptions
During the one-year study period in 2005, a total of 12
314 prescriptions for 3076 patients aged 60 years or
older (68.1% female) were included. Altogether, 2103
(68.4%; 66.4% female) of the patients were 60-74 years,
391 (12.7%; 62.9% female) were 75-79 years, and
582 (18.9%; 77.7% female) were 80 years or older. The
median age was 69 (IQR [65, 77]). Each patient had a
median of 2 (IQR [1,5]) prescriptions per year.
Diagnoses
Table 1 provides a detailed overview of treatment diag-
noses according to patient age and gender. In total,
23.5% of the reported diagnoses were diseases of the cir-
culatory system, 13.9% were cancer, 10.6% were diseases
of the musculoskeletal system and connective tissue,
8.1% were endocrine, nutritional and metabolic diseases,
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mental and behavioural disorders. Other diseases range
far behind. The most frequent single diagnoses were
essential hypertension (11.1%), breast cancer (3.5%),
heart failure (3.0%), depression (2.6%), Parkinson’sd i s -
ease (2.5%), and chronic ischemic heart disease (2.3%).
Every patient had an average of 3.33 ± 3.10 different
treatment diagnoses per year (median: 2; IQR [1,4]). In
total, 48.7% of patients had more than 2 diagnoses (3 or
4 diagnoses: 22.4%, more than 4 diagnoses: 26.3%). The
number of diagnoses increased with patient age (more
than 2 diagnoses: 60-74 years: 44.2%; 75-79 years: 50.6; >
80 years: 61.7%) and was higher for women than men
(more than 2 diagnoses: 50.6% vs. 44.8%).
Pharmacological therapy
Of the 28 961 medications prescribed, physicians
recorded a median of 1 (IQR [1,2]) drug and remedy
per patient and consultation. Every patient had a median
of 4 (IQR [2,11]) medications per year. Figure 1 provides
a detailed overview of the number of prescribed medica-
tions per patient during the one year study period.







60-74 years (n = 2127)
Hypertensive diseases [I10-I15] 25.1 23.3 28.6
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and
related tissue [C00-C75]
19.0 20.8 15.5
Mood [affective] disorders [F30-F39] 11.9 13.0 7.2
Dorsopathies [M40-M54] 10.7 10.1 12.0
Arthropathies [M00-M25] 9.1 10.1 7.1
Episodic and paroxysmal disorders* [G40-G47] 8.3 9.0 6.8
Other forms of heart disease [I30-I52] 8.3 8.1 8.6
General symptoms and signs [R50-R69] 8.2 8.5 7.7
Chronic lower respiratory diseases [J40-J47] 8.0 8.1 7.9
Diabetes mellitus [E10-E14] 6.3 4.4 10.0
75-79 years (n = 396)
Hypertensive diseases [I10-I15] 33.6 31.9 36.6
Other forms of heart disease [I30-I52] 16.4 15.0 19.0
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and
related tissue [C00-C75]
12.6 8.3 20.4
Mood [affective] disorders [F30-F39] 10.9 12.6 7.7
Ischaemic heart diseases [I20-I25] 10.6 10.2 11.3
Diabetes mellitus [E10-E14] 10.1 12.2 6.3
Dorsopathies [M40-M54] 9.8 11.8 6.3
Arthropathies [M00-M25] 9.8 10.6 8.5
Chronic lower respiratory diseases [J40-J47] 9.3 7.5 12.7
Organic, including symptomatic, mental disorders** [F00-F09] 6.8 6.7 7.0
80 years or older (n = 553)
Hypertensive diseases [I10-I15] 39.4 39.6 38.8
Other forms of heart disease [I30-I52] 32.9 33.3 22.3
Ischaemic heart diseases [I20-I25] 16.8 16.7 17.4
Arthropathies [M00-M25] 15.7 17.6 9.1
Dorsopathies [M40-M54] 12.8 12.3 14.9
Episodic and paroxysmal disorders* [G40-G47] 12.3 13.0 9.9
Organic, including symptomatic, mental disorders** [F00-F09] 11.6 11.1 13.2
Osteopathies and chondropathies [M80-M94] 9.9 12.3 1.7
Chronic lower respiratory diseases [J40-J47] 9.8 8.8 13.2
Mood [affective] disorders [F30-F39] 9.4 9.5 9.1
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and
related tissue [C00-C75]
9.4 8.6 12.4
* including sleep disorders, ** including dementia
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drugs, 23.8% were prescribed 5-10 drugs, and 12.5% of
patients were prescribed more than 10 drugs per year.
Table 2 gives a detailed overview of the medication
regimens prescribed by the participating physicians. In
total, 30.5% of the regimens could be classified as CAM
remedies alone, 54.4% as conventional pharmaceuticals
alone, and 15.1% as a combination of CAM remedies
and conventional pharmaceuticals. There were signifi-
cant differences in medication regimen according to
patient age (P < 0.001) and gender (P < 0.001), physician
specialization (P < 0.001), consultation type (P <0 . 0 0 1 ) ,
and for various diagnoses (P < 0.001). For example, the
proportion of the therapy regimen ‘only CAM treat-
ment’ decreased significantly with patient age (36.2%;
60-74 years, 23.2%; 75-79 years, and 21.7% over
80 years; P for trend < 0.001) and was higher in women
than men (32.7% vs. 25.3%; P < 0.001).
Table 3 provides an overview of the most frequently
prescribed conventional pharmaceuticals according to
age group and gender. In total, conventional pharma-
ceuticals accounted for 58.3% of all medications pre-
scribed. The most frequent substances were metoprolol
(beta-blocker; 2.4% of all conventional pharmaceuticals),
levothyroxine sodium (thyroid hormone; 1.9%), metami-
zole sodium (pyrazolone; 1.9%), acetylsaliyciclic acid
(1.6%), enalapril (ACE inhibitor; 1.6%), dopa and dopa
derivates (anti-Parkinson drug; 1.6%), and furosemide
(diuretic; 1.4%). Antihypertensive medication (e.g. cal-
cium channel blockers, diuretics, beta-blockers, angio-
tensin converting enzyme (ACE) inhibitors, angiotensin
II receptor antagonists, alpha-1 blockers, and antiadre-
nergic agents) accounted for 20.0% (n = 3390) of all
conventional drugs prescribed (11.7% of all drugs and
remedies). The most frequently prescribed substances
according to drug classes were as analgesics various
opioids (50.9% of all analgesics) and pyrazolone (meta-
mizole sodium; 33.7%), as psycholeptics benzodiazepine
derivates (28.7% of all psycholeptics) and benzodiazepine
related drugs (25.4%), as anti-dementia drugs anticholi-
nesterases (18.0% of all anti-dementia drugs) and mem-
antine (13.4%), as antidepressants amitriptyline (19.3%
of all antidepressants) and doxepin (7.5%), as anti-Par-
kinson drugs dopa and dopa-derivates (45.6% of all anti-
Parkinson drugs) and dopamine agonists (35.1%), and as
lipid modifying agents simvastatine (61.6% of all lipid
modifying agents).
CAM remedies accounted for 41.7% of all medications
prescribed (35.5% anthroposophic, 3.3% homeopathic,
2.9% phytotherapeutic). The proportion of CAM reme-
dies was significantly higher for women than for men
(33.2% vs. 46.1%; P < 0.001). Although the total number
of prescribed CAM remedies remained stable, the pro-
portion of CAM remedies decreased with patient age
while conventional drugs were prescribed more often
(48.1% 60-74 years, 32.1% 75-79 years, and 30.1% over
80 years; P for trend < 0.001). The phytopharmaceutical
ginkgo biloba was the most frequently prescribed anti-
dementia drug overall (68.6% of all anti-dementia
drugs).
Of those 124 patients who received antidementiva, 92
were given ginkgo biloba alone (74.2%) and one patient
was co-prescribed ginkgo biloba with anticholinesterases
(0.8%).
Hypericum perforatum served as a phytopharmaceuti-
cal, homeopathic or anthroposophic remedy often pre-
scribed for depression (45.5% of all antidepressants). Of
those 184 patients who received antidepressants, 69
(37.5%) were prescribed Hypericum perforatum alone,
while 4 patients were co-prescribed Hypericum perfora-
tum with amitriptyline (2.2% of all depressive patients),
and no patient was co-prescribed Hypericum perforatum
with doxepin.
Altogether, 10 271 prescriptions for a total of 976 dif-
ferent anthroposophic remedies were prescribed during
the study. Various mistletoe preparations (e.g. Abnoba-
viscum abietis®, Abnobaviscum mali®, Helixor P®, Iscador
P®) accounted for 21.7% (n = 2233) of all anthropo-
sophic remedies prescribed (7.7% of all drugs and reme-
dies). In total, mistletoe was prescribed for 81.6% (413/
506) of all patients with cancer. Other more frequent
anthroposophic remedies for particular diagnoses were
Cardiodoron® and Aurum/Belladonna comp.® for essen-
tial hypertension, Helleborus niger e planta tota® for
cancer, Oleum Strophanthi forte® for heart failure,
Solum Oil® for dorsopathies®, and hypericum and var-
ious Aurum peparations for depression.
The proportion of prescribed anthroposophic medica-
tion significantly decreased with patient age (41.4% 60-
74 years, 26.7% 75-79 years, and 25.2% over 80 years; P
for trend < 0.001) and was higher for female than male
patients (37.7% vs. 30.5%, P < 0.001). After bonferroni
correction in univariate analysis, consultation type,
Figure 1 Number of prescribed drugs per patient and year
according to gender and age group
Jeschke et al. BMC Geriatrics 2010, 10:48
http://www.biomedcentral.com/1471-2318/10/48
Page 5 of 13physician specialization, and the following diagnoses
were also found to be significant: hypertensive diseases,
cancer, arthropathies, chronic lower respiratory diseases,
diabetes mellitus, episodic and paroxysmal disorders,
ischemic heart disease, extrapyramidal and movement
disorders, dorsopathies, metabolic disorders, and disor-
ders of the thyroid gland. Diagnoses with a proportion
of anthroposophic medication over 60% were neoplasms
(71.3%), as well as diseases of the eye and adnexa
(68.6%), and less than 15% endocrine, nutritional, and
metabolic disorders (14.7%). For diseases of the circula-
tory system, the most frequent disorders, only 24.4% of
the drugs and remedies prescribed were anthropsophic
medication.
Table 4 shows the adjusted odds ratio (AOR) for the
most frequent diagnoses and other factors associated
with being prescribed an anthroposophic remedy.
Patient age and gender, as well as physician specializa-
tion, consultation type, and diagnoses, had an impact on
the choice of remedy prescribed. The AOR for receiving
an anthroposophic remedy was significantly greater than
1 for patients having their first consultation (AOR =
1.65; CI: 1.52-1.79), treatment by an internist (AOR =
1.49; CI: 1.40-1.58), female patients (AOR = 1.35; CI:










Nn % n % n %
Total 12314 3758 30.5 1858 15.1 6698 54.4
Consultation type
First 1845 664 36.0 139 7.5 1042 56.5
Follow-up 10469 3094 29.6 1719 16.4 5656 54.0
Physician specialization
GP 7956 2376 29.9 1161 14.6 4419 55.5
Internal medicine 2527 972 38.5 427 16.9 1128 44.6
Other 1831 410 22.4 270 14.7 1151 62.9
Age (y)
60-74 7320 2648 36.2 1134 15.5 3538 48.3
75-79 1762 409 23.2 239 13.6 1114 63.2
> 80 3232 701 21.7 485 15.0 2046 63.3
Sex
male 3567 901 25.3 513 14.4 2153 60.4
female 8747 2857 32.7 1345 15.4 4545 52.0
Diagnosis [ICD-10]
Diseases of the circulatory system [I00-I99] 2835 563 19.9 424 15.0 1848 65.2
Neoplasms [C00-D48] 1380 856 62.0 137 9.9 387 28.0
Diseases of the musculoskeletal system and connective tissue [M00-M99] 1211 443 36.6 206 17.0 562 46.4
Endocrine, nutritional, and metabolic diseases [E00-E90] 1103 148 13.4 141 12.8 814 73.8
Diseases of the nervous system [G00-G99] 1058 189 17.9 119 11.2 750 70.9
Mental and behavioural disorders [F00-F99] 901 260 28.9 126 14.0 515 57.2
Diseases of the digestive system [K00-K93] 763 220 28.8 147 19.3 396 51.9
Diseases of the respiratory system [J00-J99] 745 308 41.3 155 20.8 282 37.9
Symptoms, signs, and abnormal clinical and laboratory findings [R00-R99] 695 215 30.9 133 19.1 347 49.9
Diseases of the genitourinary system [N00-N99] 386 124 32.1 50 13.0 212 54.9
Diseases of the skin and subcutaneous tissue [L00-L99] 376 136 36.2 67 17.8 173 46.0
Injury, poisoning, and certain other consequences of external causes [S00-T98] 263 80 30.4 35 13.3 148 56.3
Certain infectious and parasitic diseases [A00-B99] 260 71 27.3 62 23.8 127 48.8
Diseases of the eye and adnexa [H00-H59] 103 50 48.5 19 18.4 34 33.0
Other n < 100 235 95 40.4 37 15.7 103 43.8
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Page 6 of 131.27-1.43), cancer (AOR = 4.54; CI: 4.12-4.99), arthropa-
thies (AOR = 1.36; CI: 1.19-1.55), or dorsopathies
(AOR = 1.34; CI: 1.16-1.55). The likelihood of being
prescribed an anthroposophic remedy was especially low
for patients with hypertensive diseases (AOR = 0.36; CI:
0.32-0.39), diabetes mellitus (AOR = 0.17; CI: 0.14-0.22),
or metabolic disorders (AOR = 0.17; CI: 0.13-0.22). The
interactions between hypertensive disease and age, as
well as extrapyramidal and movement disorders and age,
were found to be statistically significant (see Figure 2 for
t h eo d d sr a t i o si nt h ed i f f e r e n ta g es t r a t a )a n dw e r e
included in the model. In the case of hypertensive dis-
ease and extrapyramidal and movement disorders, the
likelihood of being prescribed an anthroposophic
remedy increased with age.
Discussion
Diagnoses
In accordance with the findings of Cheung et al., the
most common conditions were chronic diseases [24].
Most of the patients in our cohort were treated for
hypertension, cancer, depression, dorsopathies, and
arthropathies. Hypertension, ischemic heart disease, and
other forms of heart disease (i.e. heart failure) were the
primary reasons patients 80 years and older visited a
physician in our study. These diseases are also the main
reasons patients aged 80 years or older are treated in
conventional settings in Germany [25]. Compared to
elderly patients treated by conventional physicians, the
patients in this present study showed a lower proportion
of diseases associated with a modern lifestyle, such as
disorders of lipoprotein metabolism and diabetes melli-
tus [25,26]. This might be attributed to a higher educa-
tional level among patients treated by anthroposophic
physicians, resulting in a more health-conscious lifestyle.
As Unkelbach et al. has shown, patients of conventional
and anthroposophic physicians in Germany are compar-
able in many aspects (e.g. age, proportion suffering from
a chronic disease), but anthroposophic patients are
more often female, a higher proportion of patients have
a university degree, and a lower proportion are smokers
or are overweight [27]. Other studies found CAM users
tended to be younger and more educated and fewer are
hypertensive or report, for example, arthritis, depres-
sion/anxiety [4,28], or pain [29].
Due to the fact that AM is well known for pharma-
cotherapeutic options, like mistletoe-preparations for
adjuvant treatment of cancer, it is not surprising that
Table 3 Most frequent conventional drugs according to age group and gender
Medication [ATC classification] Total Gender Age (y)
Male Female 60-74 75-79 > 80
N%n% n%n%n%n%
Total 16910 100.0 5661 100.0 11249 100.0 9303 100.0 2795 100.0 4812 100.0
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
[C09]
1218 7.2 469 8.3 749 6.7 714 7.7 208 7.4 296 6.2
ANALGESICS [N02] 945 5.6 298 5.3 647 5.8 571 6.1 78 2.8 296 6.2
PSYCHOLEPTICS [N05] 823 4.9 281 5.0 541 4.8 400 4.3 144 5.2 279 5.8
DIURETICS [C03] 795 4.7 266 4.7 529 4.7 301 3.2 157 5.6 337 7.0
BETA BLOCKING AGENTS [C07] 740 4.4 275 4.9 465 4.1 453 4.9 116 4.2 171 3.6
PSYCHOANALEPTICS [N06] 711 4.2 242 4.3 469 4.2 329 3.5 135 4.8 247 5.1
CARDIAC THERAPY [C01] 648 3.8 205 3.6 358 3.2 215 2.3 116 4.1 317 6.6
ANTI-PARKINSON DRUGS [N04] 643 3.8 363 6.4 280 2.5 296 3.2 153 5.5 194 4.0
ANTITHROMBOTIC AGENTS [B01] 559 3.3 245 4.3 314 2.8 205 2.2 117 4.2 237 4.9
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
[M01]
552 3.3 148 2.6 404 3.6 316 3.4 78 2.8 158 3.3
DRUGS FOR ACID RELATED DISORDERS [A02] 506 3.0 150 2.6 356 3.2 300 3.2 57 2.0 149 3.1
CALCIUM CHANNEL BLOCKERS [C08] 489 2.9 191 3.4 298 2.6 208 2.2 125 4.5 156 3.2
THYROID THERAPY [H03] 440 2.6 63 1.1 377 3.4 319 3.4 61 2.2 60 1.2
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES [R03] 438 2.6 171 3.0 267 2.4 226 2.4 100 3.6 112 2.3
DRUGS USED IN DIABETES [A10] 426 2.5 167 3.0 259 2.3 274 2.9 76 2.7 76 1.6
MINERAL SUPPLEMENTS [A12] 422 2.5 79 1.4 343 3.0 254 2.7 44 1.6 124 2.6
ANTIBIOTICS [J01] 366 2.2 115 2.0 251 2.2 205 2.2 64 2.3 97 2.0
LIPID MODIFYING AGENTS [C10] 333 2.0 141 2.5 192 1.7 237 2.5 54 1.9 42 0.9
Other n < 300 5856 34.6 1792 31.7 4150 36.9 3480 37.4 912 32.6 1464 30.4
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Page 7 of 13our study counted for more patients with cancer in the
present study cohort [30-32]. This also applies to
depression because visiting an anthroposophic physician
has shown specific benefits in terms of quality of life for
patients suffering from depression [33]. However, this
does not directly yield a higher prescription rate of AM
drugs. Particularly in the field of depression, our physi-
cians also follow the trend of prescribing herbal reme-
dies, like St. John’s wort, which are not directly linked
to AM.
A study from Canada has shown that as patients age,
multimorbidity plays an increasingly important role in
primary care with a prevalence of 60% among people
aged 55 to 74 [34]. According to van den Akker et al.,
male patients aged 80 and over had a mean of 3.25 diag-
noses per year, whereas female patients had a mean of
3.57 [35]. Although our cohort was slightly younger
(aged 60 and older), we found a comparable value of
3.33 diagnoses. Unsurprisingly and in accordance with
other findings, the percentage of patients with
comorbidity increased with older age and was higher for
female patients [35].
Pharmacological therapy
As already stated, we found an increment in medication
directly related to the number of diagnoses. According
to Laux et al., this interrelationship is mainly influenced
by age and, to a lesser extend, by gender [36]. In the
Slone survey, which evaluated the pattern of medication
use in the ambulatory adult population of the United
States, 23% of patients aged 65 years and over took 5 or
more drugs, whereas 12% took more than 10 drugs
within one week [37]. In contrast to our study, they also
included OTC-medications in their calculations.
Another study, which evaluated characteristics of outpa-
tient prescriptions for the elderly in Taiwan, with an
average age of 78 years, found that 84% of the observed
population took 5 or more drugs per year [38]. These
findings strongly differ from our results; the number of
prescribed different drugs per patient and year was
Table 4 Multivariate logistic regression: factors associated with anthroposophic remedies
Factor AOR (95% CI)
Consultation type
Follow-up 1
First 1.65 (1.52 - 1.79)*
Physician specialization
GP 1
Internal medicine 1.49 (1.40 - 1.58)*
Other 0.76 (0.70 - 0.84)*
Age (y)** 0.97 (0.97 - 0.98)*
Sex
male 1
female 1.35 (1.27 - 1.43)*
Diagnosis (groups)
Hypertensive diseases [I10-I15] 0.36 (0.32 - 0.39)*
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of
lymphoid, haematopoietic, and related tissue [C00-C75]
4.54 (4.12 - 4.99)*
Malignant neoplasms of ill-defined, secondary, and unspecified sites [C76-C80] 2.90 (2.54 - 3.30)*
Arthropathies [M00-M25] 1.36 (1.19 - 1.55)*
Chronic lower respiratory diseases [J40-J47] 0.59 (0.50 - 0.69)*
Diabetes mellitus [E10-E14] 0.17 (0.14 - 0.22)*
Episodic and paroxysmal disorders [G40-G47] 0.53 (0.45 - 0.63)*
Ischaemic heart diseases [I20-I25] 0.71 (0.60 - 0.83)*
Extrapyramidal and movement disorders [G20-G26] 0.46 (0.37 - 0.58)*
Dorsopathies [M40-M54] 1.34 (1.16 - 1.55)*
Metabolic disorders [E70-E90] 0.17 (0.13 - 0.22)*
Disorders of thyroid gland [E00-E07] 0.54 (0.45 - 0.64)*
Interaction terms
Hypertensive diseases [I10-I15] * age 1.03 (1.02 - 1.04)*
Extrapyramidal and movement disorders [G20-G26] * age 1.04 (1.02 - 1.07)*
* OR significant different from 1; ** continuous centered variable
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Page 8 of 13Figure 2 Odds ratios for the use of anthroposophic remedies for hypertensive disease and extrapyramidal and movement disorders
stratified by age groups
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Page 9 of 13greater than 5 for only 36% of the patients and only 13%
took more than 10 drugs per year. Although some fac-
tors, like the occurrence of polypharmacy, were more
likely in female patients and in older patients [37,39],
one has to be aware that a comparison of results has to
take into account the different healthcare settings and
policies in which the studies were conducted.
In the field of anthroposophic medicine, pharmacolo-
gical treatment is based on an integrative concept that
combines conventional and CAM approaches depending
on the disease and it is carried out on a patient-by-
patient basis. Regardless of diagnosis, CAM remedies
alone were prescribed in 31% of cases, conventional
pharmaceuticals alone in 54% of cases, and a combina-
tion of CAM remedies and conventional pharmaceuti-
cals in 15% of cases. The likelihood of receiving CAM
remedies alone was highest for patients with neoplasms
(62% of all prescriptions for this group of patients) and
lowest for patients with endocrine, nutritional, and
metabolic disorders (13%). It is interesting to note that
CAM medications were mainly prescribed for patients
with cancer and dementia, whereas the majority of
patients with cardiovascular and metabolic disorders
were prescribed conventional medications. This is in
accordance with a previous analysis [13]; however, there
is no direct explanation for this trend. One hypothesis is
that no additional treatment is used for diseases that
can be controlled with conventional treatment, whereas
in terms of cancer, for example, patients and physicians
more often seek an additional treatment.
Of course, these observations do not infer that condi-
tions like cancer are not conventionally treated (e.g. by
chemotherapy or surgery). In such cases, AM is pre-
scribed in addition to conventional treatment sometimes
over a longer period of time [40]. Mistletoe in this
r e s p e c tw a st h em o s tf r e q u e n tly prescribed anthropo-
sophic remedy. These findings partially confirm those
reported in a study by Hamre et al., who also found
high prescription rates for anthroposophic remedies in
patients with cancer [41]. According to a recently pub-
lished review, supportive mistletoe therapy seems safe
and particularly beneficial for the quality of life of adult
patients with solid tumours [30]. However, anthropo-
sophic remedies were also prescribed quite frequently
for dorsopathies alone or as a substitute for conven-
tional remedies, showing an improvement in health-
related quality of life and long-term stabilization [42].
For elderly patients with depression, various Hypericum
and Aurum preparations were frequently prescribed. In
accordance with the results of an earlier study, anthro-
posophic remedies, such Cardiodoron® and Aurum/Bel-
ladonna comp.®, were frequently prescribed for
hypertension, mainly as adjuncts to classic antihyperten-
sive therapy most likely as a way to stimulate and
harmonize the rhythmic system and to assist the body
in regulating blood pressure with its own resources
[19,43].
Patient gender was associated with significant differ-
ences in prescription rates in the present study. This is
in accordance with the results of several studies, which
found that gender had an influence on the rate at which
different medications were prescribed for adults and the
female sex was a predictor of CAM use in the elderly
[44-46]. The present study showed that older patients
are less likely to receive an anthroposophic remedy.
Compared to GPs, internists prescribed anthroposophic
remedies more often to patients and issued a signifi-
cantly larger number of conventional and CAM medica-
tions per patient. This may be attributed to a tendency
among patients to seek help from specialists in cases of
severe disease.
With regard to conventional drugs, only minor differ-
ences were observed in prescription rates in the present
study compared to those in the German Drug Prescrip-
tion Report (Arzneimittelverordnungsreport) from 2006,
an annual publication listing, among other data, of the
proportion of prescriptions most frequently issued in
Germany [47]. Indeed, in the present study, patients
were most likely to receive medication for hypertension,
followed by analgesics, psycholeptics, psychoanaleptics,
and anti-Parkinson drugs.
The successful treatment of hypertension in elderly
patients seems to be the most important drug therapy that
reduces the agglomeration of morbidity at the end of life
a ss h o w ni nt h eH Y V E T - t r i a l(Hypertension in the Very
Elderly Trial) [48,49]. Our findings suggest that such
patients are mainly treated with ACE-antagonists and
diuretics. While the amount of diuretics increased with
age, the amount of beta-blockers and ACE-inhibitors
decreased. In accordance with other studies, in younger
populations we were able to show that male patients were
more likely to be prescribed an ACE-antagonist [50,51].
Altogether, hypertension was treated in accordance with
the German guidelines. We give a more detailed analysis
of hypertensive treatment elsewhere [43].
Another important condition is dementia. In our set-
ting, Ginkgo biloba is the most frequently prescribed
complementary drug for dementia. The appraisal of evi-
dence for the treatment of dementia is inconsistent [52].
One of the latest studies showed that ginkgo is an effec-
tive adjuvant treatment option for elderly patients with
mild cognitive impairment [53], whereas the German
Institute for Quality and Efficiency in Health Care
(IQWIG) found only a benefit for the 240 mg prepara-
tion and criticized the heterogeneity of the study results
[54]. However, German GPs vote ginkgo preparations
for dementia as equally effective as anticholinesterases
and memantine [55].
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lized elderly people, St. John’sw o r t( Hypericum perfora-
tum) is the most often prescribed antidepressant
followed by amitriptylin and doxepin [56]. We were able
to confirm these results in our primary care network.
Also, other age related diseases like Parkinson’s disease
showed similar prescribing patterns found in other stu-
dies with a strong increase in male patients and patients
aged 70 years and older [57-59].
Implications for practice and policy
The provision of CAM in primary care still needs further
education and information from primary care health pro-
fessionals about its potential and limitations, particularly
when combining CAM remedies with conventional drugs.
The chronological dimension of pharmacotherapy in the
treatment of elderly patients and the occurrence of critical
combinations is a topic of notably high interest to health
services research. Although we did not find a significant
amount of such events, our network offers possibilities to
further research this topic. In addition, the associations
between AM prescribing and factors like age, sex, consul-
tation type, and diagnoses do not, to our knowledge, have
a correlation in other prescription studies in primary care
and should also be investigated more closely. Finally, the
use of over-the-counter (OTC) medications by elderly
patients is a field of interest. With only limited data on the
use of CAM and OTC drugs in the elderly, physicians
should record their use systematically, which would make
them available for research in settings like this one.
Limitations
The present study has some limitations. Firstly, although
physician prescribing data were subjected to an internal
review as described above, coding inaccuracies cannot
be ruled out entirely. In contrast to other methods of
conducting epidemiological surveys for prescribing pat-
terns in primary care, QuaDoSta is linked to the existing
computerized patient documentation systems of physi-
cians and can be incorporated fully into their daily rou-
tines, avoiding typical biases, such as missing data or
double entries. Although such an approach may not
have an impact on external validity, it can increase the
internal validity of data [22]. According to Himmel
(2006), we nevertheless can assume that relevant data
like patient age, gender, and prescriptions are suffi-
ciently documented by the physicians and that it is pos-
s i b l et ou s er o u t i n ed a t af o ri d e n t i f i c a t i o na n d
classification of therapeutic actions, as well as for quality
assurance in ambulatory patient care [60]. Secondly,
additional data on specific diagnoses, such as informa-
tion on disease severity and duration or the impact of
these factors on the observed prescribing patterns, were
unavailable. Thirdly, we were unable to obtain data on
the subsequent medication use of patients who decided
to switch physicians; similarly, no data were available for
cases in which physicians provided patients with a refer-
ral for treatment by a specialist or hospital. Up to now,
we also were not effectual in implementing our technol-
ogy in a comparison group of conventional physicians.
Finally, data on patient self-medication with CAM reme-
dies or OTC drugs were unavailable. This may explain
why only 36% of patients in this study took more than 5
medications while the numbers reported in the literature
differ significantly.
Conclusion
This study of a large sample of elderly people under-
going anthroposophic primary care in Germany is the
first to provide a consecutive and systematic overview
of pharmacotherapy in everyday conditions. During the
12-month study period, anthroposophic remedies
accounted for 36% of all medications prescribed.
Regardless of diagnosis, the likelihood of receiving an
anthroposophic remedy was higher for female patients,
patients having their first consultation, and patients
treated by an internist. Cancer, arthropathies, and dor-
sopathies were the diagnoses for which anthroposophic
remedies were prescribed most frequently. However, the
likelihood of being prescribed an anthroposophic
remedy decreased with patient age and was especially
low for patients with hypertensive diseases, diabetes
mellitus, or metabolic disorders.
The findings show that physicians who practice
anthroposophic medicine prescribe both conventional
and complementary medicine, thus taking an integrative
approach. Our study may facilitate further CAM-
research on indications of, for example, dementia or
adverse drug reactions in the elderly.
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